Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clinton Yam

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
The Oncologist|August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast CancerReva K Basho, Clinton Yam, Michael Gilcrease, et al.
Investigational New Drugs|September 28, 2020
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancerClinton Yam, Gaiane M Rauch, Tanbin Rahman, et al.
American Journal of Cancer Research|April 6, 2019
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cellsYe Han, Mei-Kuang Chen, Hung-Ling Wang, et al.
Investigational New Drugs|January 6, 2019
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II studyClinton Yam, Francisco J Esteva, Miral M Patel, et al.
Cancer Research|August 1, 2022
MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast CancerChengyue Wu, Angela M Jarrett, Zijian Zhou, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 28, 2021
Effector memory cytotoxic CD3<sup>+</sup>/CD8<sup>+</sup>/CD45RO<sup>+</sup> T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancerXiangjie Sun, Jie Zhai, Baohua Sun, et al.
The New England Journal of Medicine|January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast CancerSara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
JCO Precision Oncology|March 14, 2024
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer SubtypesReva K Basho, Li Zhao, Jason B White, et al.
European Journal of Radiology|February 22, 2022
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancerJorge E Jimenez, Abeer Abdelhafez, Elizabeth A Mittendorf, et al.
American Journal of Cancer Research|March 21, 2020
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancerYu-Yi Chu, Clinton Yam, Mei-Kuang Chen, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
The Oncologist|August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast CancerReva K Basho, Clinton Yam, Michael Gilcrease, et al.
Investigational New Drugs|September 28, 2020
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancerClinton Yam, Gaiane M Rauch, Tanbin Rahman, et al.
American Journal of Cancer Research|April 6, 2019
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cellsYe Han, Mei-Kuang Chen, Hung-Ling Wang, et al.
Investigational New Drugs|January 6, 2019
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II studyClinton Yam, Francisco J Esteva, Miral M Patel, et al.
Cancer Research|August 1, 2022
MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast CancerChengyue Wu, Angela M Jarrett, Zijian Zhou, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 28, 2021
Effector memory cytotoxic CD3<sup>+</sup>/CD8<sup>+</sup>/CD45RO<sup>+</sup> T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancerXiangjie Sun, Jie Zhai, Baohua Sun, et al.
The New England Journal of Medicine|January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast CancerSara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
JCO Precision Oncology|March 14, 2024
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer SubtypesReva K Basho, Li Zhao, Jason B White, et al.
European Journal of Radiology|February 22, 2022
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancerJorge E Jimenez, Abeer Abdelhafez, Elizabeth A Mittendorf, et al.
American Journal of Cancer Research|March 21, 2020
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancerYu-Yi Chu, Clinton Yam, Mei-Kuang Chen, et al.
Pageof 7